Brian Hess to Rituximab
This is a "connection" page, showing publications Brian Hess has written about Rituximab.
Connection Strength
0.045
-
Phase I Trial of N-803, an IL15 Receptor Agonist, with Rituximab in Patients with Indolent Non-Hodgkin Lymphoma. Clin Cancer Res. 2021 06 15; 27(12):3339-3350.
Score: 0.045
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.